Novavax, a biotechnology company focused on vaccine development, employs roughly 850 people worldwide. Recent staffing data show 23 new hires alongside 122 departures, indicating a net decrease in overall headcount. The hiring and attrition figures translate to a modest intake of about 3 percent of the workforce versus departures of roughly 14 percent, suggesting the organization is recalibrating its staffing levels while continuing operations in research, manufacturing, and corporate functions.
Employee distribution is led by the “Other” category at 225 team members, followed closely by Engineering with 217 employees who support research, development, and manufacturing technology. Business Management (103), Operations (98), and Finance & Administration (76) form the core corporate groups that enable day-to-day business execution. Sales & Support accounts for 69 employees, while Healthcare specialists number 58; smaller groups such as Consulting and Education round out the remaining headcount. The mix reflects a concentration on scientific expertise complemented by the infrastructure needed to bring vaccines to market.
Novavax maintains a strong Mid-Atlantic footprint. Washington, DC hosts the largest cluster with 139 employees, and the company’s long-standing presence in Gaithersburg, MD contributes a further 98 employees. Additional Maryland hubs include Rockville, Frederick, Germantown, Clarksburg, and Bethesda, highlighting the state’s role in biotechnology manufacturing and research. Outside the region, New York City employs 19 people and Philadelphia 15, while a dispersed group of 143 employees is classified under “Other,” indicating remote or smaller satellite sites supporting nationwide operations.